Rocket Pharmaceuticals (RCKT) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$50.3 million.

  • Rocket Pharmaceuticals' Profit After Tax rose 2456.12% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 665.18%. This contributed to the annual value of -$258.7 million for FY2024, which is 535.48% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Profit After Tax of -$50.3 million as of Q3 2025, which was up 2456.12% from -$68.9 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Profit After Tax peaked at -$34.5 million during Q2 2021, and registered a low of -$69.6 million during Q2 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' median Profit After Tax value was -$59.7 million (recorded in 2023), while the average stood at -$56.6 million.
  • Data for Rocket Pharmaceuticals' Profit After Tax shows a peak YoY increase of 2736.39% (in 2021) and a maximum YoY decrease of 7234.53% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Profit After Tax stood at -$44.2 million in 2021, then tumbled by 50.8% to -$66.7 million in 2022, then rose by 10.59% to -$59.7 million in 2023, then dropped by 1.12% to -$60.3 million in 2024, then rose by 16.57% to -$50.3 million in 2025.
  • Its last three reported values are -$50.3 million in Q3 2025, -$68.9 million for Q2 2025, and -$61.3 million during Q1 2025.